Get the Stockscreener App
8.66
6.00%
0.49
Fennec Pharmaceuticals Inc stock is traded at $8.66, with a volume of 166.03K.
It is up +6.00% in the last 24 hours and up +1.05% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$8.17
Open:
$8.27
24h Volume:
166.03K
Relative Volume:
2.08
Market Cap:
$240.87M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-14.20
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
+3.59%
1M Performance:
+1.05%
6M Performance:
+30.23%
1Y Performance:
+57.45%
1-Day Range:
$8.105
$8.73
1-Week Range:
$7.5678
$8.73
52-Week Range:
$3.96
$9.42
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
8.66 | 228.22M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2025 Earnings Call Transcript - Insider Monkey
Chart overlay techniques for tracking Fennec Pharmaceuticals Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser
Is Fennec Pharmaceuticals Inc. a candidate for recovery playWeekly Trade Summary & Consistent Profit Focused Trading Strategies - Newser
Can a trend reversal in Fennec Pharmaceuticals Inc. lead to recoveryTrade Exit Report & Community Consensus Picks - Newser
Is Fennec Pharmaceuticals Inc. forming a bottoming baseShort Setup & Real-Time Market Trend Scan - Newser
Fennec Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Movers & Low Drawdown Momentum Ideas - Newser
Fennec Pharmaceuticals Inc. stock chart pattern explainedMarket Movement Recap & Expert Approved Momentum Ideas - Newser
What data driven models say about Fennec Pharmaceuticals Inc.’s futureQuarterly Portfolio Report & Verified Momentum Stock Watchlist - Newser
Fennec Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results - AInvest
What moving averages say about Fennec Pharmaceuticals Inc.July 2025 Market Mood & Breakout Confirmation Alerts - Newser
Regression Model Predicts Rangebound Movement in Fennec Pharmaceuticals Inc.2025 Volume Leaders & Daily Profit Maximizing Tips - newsyoung.net
Fennec Pharmaceuticals Reports Strong Q2 2025 Results and Expands Global Reach - MSN
Automated trading signals detected on Fennec Pharmaceuticals Inc.Day Trade & Free Community Consensus Stock Picks - Newser
What candlestick patterns are forming on Fennec Pharmaceuticals Inc.Entry Point & Advanced Technical Signal Analysis - Newser
Published on: 2025-08-18 22:10:55 - Newser
Fennec Pharmaceuticals Inc. Recovers — But Is It Sustainable2025 AllTime Highs & Low Drawdown Investment Ideas - Newser
Can trapped investors hope for a rebound in Fennec Pharmaceuticals Inc.Trade Risk Summary & Detailed Earnings Play Alerts - Newser
Wedbush Forecasts Weaker Earnings for Fennec Pharmaceuticals - Defense World
Using data filters to optimize entry into Fennec Pharmaceuticals Inc.July 2025 Patterns & Weekly High Momentum Picks - Newser
Full technical analysis of Fennec Pharmaceuticals Inc. stockBreakout Watch & Low Risk High Win Rate Picks - Newser
FY2025 EPS Estimates for Adherex Technologies Cut by Wedbush - Defense World
Published on: 2025-08-18 02:32:05 - Newser
How to manage a losing position in Fennec Pharmaceuticals Inc.2025 Key Lessons & Weekly Breakout Stock Alerts - Newser
Fennec Pharmaceuticals Inc. stock outlook for YEAR2025 Bull vs Bear & Expert-Curated Trade Recommendations - Newser
How Fennec Pharmaceuticals Inc. stock performs during market volatilityMarket Performance Report & High Accuracy Trade Alerts - Newser
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - ca.finance.yahoo.com
Fennec Pharmaceuticals Inc. Ranks High in Smart Money TrackerWeekly Earnings Recap & Verified Momentum Watchlists - metal.it
Adherex Technologies (NASDAQ:FENC) Raised to “Buy” at Wall Street Zen - Defense World
Fennec Pharmaceuticals Inc. Stock Fails to Break Resistance Traders ReactJuly 2025 Selloffs & Long-Term Growth Portfolio Plans - metal.it
Fennec Pharmaceuticals’ Promising Growth and Market Potential Drive Buy Rating - TipRanks
Fennec Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
Measuring Fennec Pharmaceuticals Inc.’s beta against major indices2025 Market Outlook & Risk Managed Investment Signals - Newser
How to interpret RSI for Fennec Pharmaceuticals Inc. stockMarket Growth Summary & Free High Return Stock Watch Alerts - Newser
Fennec Pharmaceuticals Reports 33% YoY Revenue Growth, Eyes EU Expansion - AInvest
Fennec Pharmaceuticals 2025 Q2 Earnings Narrowing Losses with 43.2% Net Income Improvement - AInvest
Will Fennec Pharmaceuticals Inc. stock go up soonInsider Buying & Expert Verified Stock Movement Alerts - Newser
Fennec Pharmaceuticals Q2 2025: Unpacking Key Contradictions in Patient Adherence, Production Timelines, and Market Strategies - AInvest
Fennec Q2 Sales Jump 33 Percent - The Motley Fool
Transcript : Fennec Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):